PL377215A1 - Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego - Google Patents

Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego

Info

Publication number
PL377215A1
PL377215A1 PL377215A PL37721503A PL377215A1 PL 377215 A1 PL377215 A1 PL 377215A1 PL 377215 A PL377215 A PL 377215A PL 37721503 A PL37721503 A PL 37721503A PL 377215 A1 PL377215 A1 PL 377215A1
Authority
PL
Poland
Prior art keywords
receptor ligands
benzimidazole derivatives
vanilloid receptor
vanilloid
benzimidazole
Prior art date
Application number
PL377215A
Other languages
English (en)
Inventor
Chenera Balan
Yunxin Bo
Celia Dominguez
Christopher H. Fotsch
Vijay K. Gore
Vu Van Ma
Mark H. Norman
Vassil I. Ognyanov
Yi-Xin Qian
Xianghong Wang
Ning Xi
Shimin Xu
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of PL377215A1 publication Critical patent/PL377215A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL377215A 2002-10-17 2003-10-16 Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego PL377215A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41979102P 2002-10-17 2002-10-17

Publications (1)

Publication Number Publication Date
PL377215A1 true PL377215A1 (pl) 2006-01-23

Family

ID=32108141

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377215A PL377215A1 (pl) 2002-10-17 2003-10-16 Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego

Country Status (10)

Country Link
US (2) US7582761B2 (pl)
EP (1) EP1551811A1 (pl)
JP (1) JP2006505570A (pl)
AR (1) AR043053A1 (pl)
AU (1) AU2003301436A1 (pl)
CA (1) CA2501539A1 (pl)
MX (1) MXPA05003948A (pl)
PL (1) PL377215A1 (pl)
TW (1) TW200418807A (pl)
WO (1) WO2004035549A1 (pl)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
ES2397389T3 (es) 2003-07-30 2013-03-06 Xenon Pharmaceuticals Inc. Derivados de piridilo y su uso como agentes terapéuticos
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
EP1758895A1 (en) 2004-06-17 2007-03-07 Wyeth a Corporation of the State of Delaware Gonadotropin releasing hormone receptor antagonists
BRPI0512239A (pt) * 2004-06-17 2008-02-19 Wyeth Corp processos para preparação de antagonistas de receptores de hormÈnios liberadores de gonatropina
WO2006004793A2 (en) * 2004-06-28 2006-01-12 Janssen Pharmaceutica Nv Hetero isonipecotic modulators of vanilloid vr1 receptor
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101083986A (zh) 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
SE0402284D0 (sv) * 2004-09-21 2004-09-21 Astrazeneca Ab New heterocyclic amides
AU2005295752A1 (en) * 2004-10-15 2006-04-27 Amgen Inc. Imidazole derivatives as vanilloid receptor ligands
EP1861387B1 (en) * 2005-01-28 2014-04-16 Daewoong Pharmaceutical Co., Ltd. Benzimidazole derivatives and pharmaceutical compositions thereof
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
GB0525957D0 (en) * 2005-12-21 2006-02-01 Astrazeneca Ab Methods
UY30048A1 (es) * 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP2009541454A (ja) * 2006-07-03 2009-11-26 ノイロサーチ アクティーゼルスカブ モノアミン再摂取阻害剤及びカリウムチャネル活性剤の併用
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
CN101547923A (zh) 2006-12-07 2009-09-30 弗·哈夫曼-拉罗切有限公司 作为via受体拮抗剂的螺环-哌啶衍生物
JP2010511654A (ja) 2006-12-07 2010-04-15 エフ．ホフマン−ラ ロシュ アーゲー スピロ−ピペリジン誘導体
MX2009005544A (es) 2006-12-08 2009-06-05 Hoffmann La Roche Indoles.
KR101050558B1 (ko) 2006-12-08 2011-07-19 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항제로서 작용하는 인돌
WO2008075196A1 (en) * 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives
CN101563324A (zh) 2006-12-22 2009-10-21 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
EP2142529B1 (en) * 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
CA2685121A1 (en) * 2007-04-27 2008-11-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
CA2690953C (en) 2007-06-29 2012-10-02 Pfizer Inc. Benzimidazole derivatives
WO2009096701A2 (en) 2008-01-28 2009-08-06 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
CN101983197B (zh) * 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
JP5438103B2 (ja) 2008-07-02 2014-03-12 アモーレパシフィック コーポレイション バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
WO2010065668A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
SG174125A1 (en) 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
WO2010135568A1 (en) 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and their use to treat cancer
US8680098B2 (en) 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
CA2800578A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
US8921373B2 (en) 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
EP2621913B1 (en) 2010-10-01 2014-11-19 Bristol-Myers Squibb Company Substituted benzimidazole and imidazopyridine compounds useful as cyp17 modulators
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
JP6130827B2 (ja) 2011-05-17 2017-05-17 塩野義製薬株式会社 ヘテロ環化合物
KR101913619B1 (ko) * 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
RS55701B1 (sr) 2011-06-22 2017-07-31 Purdue Pharma Lp Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe
US20150376198A1 (en) * 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
JP6377245B2 (ja) * 2014-03-24 2018-08-22 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Ｓｍｏ阻害剤としてのキノリン誘導体
EP3280715B1 (en) 2015-04-10 2020-11-25 Beigene, Ltd. NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES
CN111417394B (zh) * 2017-10-19 2023-11-07 帝人制药株式会社 苯并咪唑衍生物及其用途
US11759461B2 (en) 2017-10-30 2023-09-19 The Scripps Research Institute Small molecule inhibitors of cancer stem cells and mesenchymal cancer types
US11472788B2 (en) 2017-11-25 2022-10-18 Beigene, Ltd. Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
KR102811265B1 (ko) * 2019-04-11 2025-05-23 데이진 화-마 가부시키가이샤 벤즈이미다졸 유도체 및 이들의 용도
US20220227762A1 (en) * 2019-05-22 2022-07-21 Beigene, Ltd. Amide-substituted imidazo compounds as selective inhibitors of indoleamine 2,3-dioxygenases
WO2023001794A1 (en) * 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
US20250145640A1 (en) 2021-08-10 2025-05-08 Syngenta Crop Protection Ag 2,2-difluoro-5h-[1,3]dioxolo[4,5-f]isoindol-7-one derivatives as pesticides
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
AU2076299A (en) * 1998-01-30 1999-08-16 Meiji Seika Kaisha Ltd. Phenylpiperazine derivatives as integrin alphavbeta3 antagonists
DK1133477T3 (da) 1998-11-27 2004-06-21 Abbott Gmbh & Co Kg Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
MXPA02000120A (es) * 1999-06-28 2002-07-02 Janssen Pharmaceutica Nv Inhibidores de la replicacion del virus sincitial respiratorio.
IL153884A0 (en) * 2000-07-20 2003-07-31 Neurogen Corp Capsaicin receptor ligands
AU2001277754B2 (en) 2000-08-10 2005-09-29 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
DE10134775A1 (de) 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10135050A1 (de) 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
AU2003212882A1 (en) 2002-02-01 2003-09-02 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain

Also Published As

Publication number Publication date
AU2003301436A1 (en) 2004-05-04
US7582761B2 (en) 2009-09-01
US20090143575A1 (en) 2009-06-04
MXPA05003948A (es) 2005-06-17
AR043053A1 (es) 2005-07-13
EP1551811A1 (en) 2005-07-13
JP2006505570A (ja) 2006-02-16
CA2501539A1 (en) 2004-04-29
WO2004035549A1 (en) 2004-04-29
TW200418807A (en) 2004-10-01
US8026241B2 (en) 2011-09-27
US20040152690A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
AP1916A (en) Purine compounds and use thereof as cannabinoid receptor ligands
AU2003238597A8 (en) Benzimidazole compounds and their use as estrogen agonists/antagonists
IL165810A0 (en) Novel benzimidazole derivatives
IL199668A0 (en) New benzimidazole derivatives
EG24590A (en) Benzimidazole and pyridylimidazole derivative as ligands gabaa receptors
IL175252A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
EG24470A (en) Biphenyl derivatives and their use as fungicides
AU2003294249A8 (en) Hetero-substituted benzimidazole compounds and antiviral uses thereof
IL166396A0 (en) Vanilloid receptor ligands and their use in treatments
IL165280A0 (en) 4-Substituted imidazole-2-thiones and imidazol-2-ones as agpmosts of the alpha-2b and alpha-2c adrenergic receptors
ZA200702131B (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof l
MXPA03006524A (es) Derivados heterociclicos novedosos de amidas y su uso como ligandos para receptor d3 de dopamina.
AU2002352476A8 (en) Urea derivatives and their use as vanilloid receptor antagonists
PL370657A1 (pl) Pochodne chinazolinonowe i ich zastosowanie jako agonistów CB
HUP0401756A3 (en) Substituted benzimidazole compounds and their use
IL172023A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IS8220A (is) Bensímídasólafleiður, blöndur sem innihalda þær, framleiðsla þeirra og notkun
PL1641787T3 (pl) Podstawione diketopiperazyny i ich zastosowanie jako antagonistów oksytocyny
GB0524575D0 (en) Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands
AU2003303068A1 (en) Carbazole derivatives and their use as npy-5 antagonists
HK1104822A (en) Benzimidazole derivatives and their use as cannabinoid receptor ligands
HK1104819A (en) Benzimidazole derivatives and their use as cannabinoid receptor ligands i
SI1558615T1 (sl) Purinske spojine in uporaba le-teh kot ligandov kanabinoidnega receptorja
GB0524576D0 (en) Benzotriazepine derivatives and their use use as gastrin and cholecystokinin receptor ligands
ZA200600676B (en) Pyridazinyl-piperazines and their use as histamine H3 receptor ligands

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)